巴黎高等商學院

2023年1月19日

美國東部標準時間2023年1月19日上午07:00，波士頓和康涅狄格州西黑文——(美國商業資訊)——創造新型精準抗癌免疫療法的生物技術公司Normunity, Inc .今天宣布任命MBA Olga Granaturova為首席運營官兼首席業務官。Granaturova女士在全球生物製藥行業擁有超過25年的多學科經驗，包括公司戰略、業務發展、研發組織、投資組合管理、監管和商業化戰略，在不同規模和不同發展階段的生物技術和製藥公司。“我們很高興歡迎Olga加入Normunity領導團隊。她在業務創建、融資和業務發展方麵的實踐經驗將在我們的持續發展中發揮至關重要的作用，”Normunity創始首席執行官Rachel Humphrey醫學博士說。“Olga的創業精神和科學背景非常適合我們的團隊，因為我們意識到我們在免疫腫瘤學方麵的新機製帶來了巨大的機會，並建立了一家世界級的生物技術公司。Granaturova女士說:“我無法想象這是加入Normunity的一個更激動人心的時刻和機會，因為該公司正在用新的免疫正常化方法來對抗癌症。”“我期待著推動下一階段的發展，以幫助Normunity實現其作為免疫腫瘤學領域藥物創新者的願望，並有可能為癌症患者創造許多改變生活的藥物。”Olga Granaturova的豐富經驗涵蓋了從研發到商業發布的整個價值鏈，她在融資、許可、合作和並購交易等業務職能方麵擁有深厚的專業知識。加入Normunity之前，她曾擔任Parthenon Therapeutics(一家創造新型抗癌療法的生物技術公司)的聯合創始人兼首席運營官。基於她在帕台農神廟的業務領導角色，以及在Evotec的業務發展副總裁和生命科學谘詢公司LENUS Group的創始人和管理合夥人，她作為創始人，天使投資人和創業導師，在生物技術初創公司的創建方麵擁有實踐經驗。在職業生涯早期，Olga曾在頂級製藥公司任職，包括在默克公司擔任全球監管開發負責人，在輝瑞公司擔任藥物發現科學家。 Over the course of her career, Olga has led teams to deliver 20 different clinical candidates, 3 drug launches, and several multi-year, multi-million dollar deals. In addition, Olga is co-founder and president of Brighter Ventures, a nonprofit organization advancing women-led entrepreneurship, and she serves on the board of Parthenon Therapeutics and Coucou Nous Voilou, a pediatric oncology nonprofit organization. She received a BS in Pharmaceutical Sciences from SUNY at Buffalo and a TRIUM Global MBA from the NYU Stern School of Business, HEC Paris and the London School of Economics, and was recently named to Inc.’s Female Founders 100 List, honoring women whose innovations and ideas are making the world into a better place. About Normunity Normunity, Inc ., is a biotechnology company creating a new class of precision immuno-oncology medicines, called immune normalizers, that target novel mechanisms that free the body’s normal immunity against cancer. Based on an ongoing, interactive academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is targeting newly discovered mechanisms of immune disruption in cancer based on proprietary discovery platforms that elucidate the complex interactions between human cancer and the immune system. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. Normunity is located in Boston, Mass. and West Haven, Conn. For more information, please visit www.normunity.com and follow us on LinkedIn . Contacts 914-204-6412